Salbutamol vs placebo/no treatment
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
- no estimate extracted4 studies · 338 participantsLow
Findings
What do systematic reviews say?
4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only
No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Salbutamol vs placebo/no treatment
Duration of mechanical ventilation · patients with the management of transient tachypnea of the newborn
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Salbutamol vs placebo/no treatment
Pneumothorax · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes pneumothorax (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- no estimate extracted1 study · 80 participantsVery low
Antihypertensive drug therapy vs placebo or no treatment
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes onlyRR 1.02 [0.74, 1.4]3 studies · 930 participantsVery low
Antihypertensive drug therapy vs placebo or no treatment
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes onlyRR 1.09 [0.77, 1.55]3 studies · 930 participantsVery low
Antihypertensive drug therapy vs placebo or no treatment
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes onlyRR 1.02 [0.89, 1.16]3 studies · 930 participantsVery low
Antihypertensive drug therapy vs placebo or no treatment
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes onlyRR 0.82 [0.57, 1.17]2 studies · 915 participantsVery low
Antihypertensive drug therapy vs placebo or no treatment
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes onlyRR 3.09 [1.69, 5.66]1 study · 522 participantsVery low
Carisbamate vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.36 [1.14, 1.62]4 studies · 2211 participantsModerate
Carisbamate vs placebo
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).
1 finding from 1 review
- RR 2.43 [0.84, 7.03]1 study · 540 participantsVery low
Carisbamate vs placebo
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.32 [0.82, 2.12]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.8 [0.78, 4.17]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy
Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).
1 finding from 1 review
- RR 1.1 [0.93, 1.3]2 studies · 1084 participantsLow
Carisbamate vs placebo
Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
- RR 2.06 [1.23, 3.44]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.28, 2.58]4 studies · 2211 participantsLow
Combination therapy vs placebo
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 1792 participantsLow
Combination therapy vs placebo
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 991 participantsVery low
Combination therapy vs placebo
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes onlyRR 1.24 [1.04, 1.47]3 studies · 1848 participantsModerate
Combination therapy vs placebo
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether combination therapy changes AUR compared with placebo (very low certainty).
1 finding from 1 review
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes onlyRR 1.94 [0.41, 9.08]5 studies · 2369 participantsVery low
Combination therapy vs placebo
Surgical intervention – not reported · men with lower urinary tract symptoms secondary to benign prostatic obstruction
The review found no eligible studies for this question.
1 finding from 1 review
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found